title: A retrospective study of hepatitis B mother-to-child transmission prevention and postvaccination serological test results of infants at risk of perinatal transmission in two counties of middle China.
abstract: Approximately, 240 million people have chronic hepatitis B worldwide, with mother-to-child-transmission (MTCT) accounting for most cases. Therefore, Henan Province, China launched a public health programme to prevent MTCT. To determine the efficacy of this health programme, a survey was carried out in Huixian and Xinan counties, which are located in northern and western Henan. All infants born in these two counties between January 1, 2013 and March 31, 2014 to a mother positive for hepatitis B surface antigen (HBsAg) were surveyed. In total, there were 438 mother-infant pairs. A blood sample was collected from all mothers and infants and the following Hepatitis B virus (HBV) markers, antibodies, and antigens were measured: HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe, and HBV-DNA. All mothers and 5.3% (23/438) of the infants were HBsAg positive. All infants received three doses of the hepatitis B vaccine (HepB) and the postvaccination serological test (PVST) showed that the appropriate interval for PVST may be 1-8 months after the final HepB dose. Multivariable analysis showed that infants without a timely first and second dose of the HepB, with an HBeAg-positive mother and mothers who had not received hepatitis B immune globulin during pregnancy were implicated in MTCT. The stratified analysis using maternal HBeAg as a marker showed that maternal HBeAg may be a strong risk factor for MTCT. To prevent MTCT in middle China, several courses of action are recommended. The first is to optimize the screening method for the mother to allow HBeAg and HBsAg-positive mothers to receive medical treatment during pregnancy and a timely birth dose of the vaccine to all infants. Second, all infants with an HBsAg-positive mother should be tested for anti-HBs and HBsAg at 7-14 months old and any anti-HBs-nonresponse infants should receive an additional three dosesof the vaccine.
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: G
authors.identifier: 0000-0002-1102-0926
authors.initials: G
authors.lastname: Yonghao
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: D
authors.initials: D
authors.lastname: Pumei
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Jianhui
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: X
authors.initials: X
authors.lastname: Jin
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Yanyang
authors.affiliation: Henan Centre for Disease Control and Prevention, Zhengzhou, China.
authors.forename: W
authors.initials: W
authors.lastname: Zhe
mesh_terms: D000293:Adolescent; D000328:Adult; D002681:China; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage*; D006513:Hepatitis B e Antigens / Q000097:blood*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D012189:Retrospective Studies; D012307:Risk Factors; D012698:Serologic Tests; D055815:Young Adult
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D006513:Hepatitis B e Antigens
keywords: hepatitis B virus; mother-to-child transmission; post-exposure prophylaxis; postvaccination serological test